Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

958 - Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Supportive Care and Symptom Management;  Breast Cancer


Yukinori Sakata


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


Y. Sakata1, H. Iwata2, H. Ikezawa2, R. Fudetani2, D. Tonoda2, Y. Uchida2, H. Hasegawa2, T. Matsuoka2

Author affiliations

  • 1 Oncology Medical Department, Eisai Co., Ltd., 112-8088 - Tokyo/JP
  • 2 Oncology Medical Department, Eisai Co., Ltd., Tokyo/JP


Abstract 958


Eribulin mesylate (ERI), a nontaxane microtubule dynamics inhibitor, has antitumor activity and can prolong overall survival in patients with recurrent breast cancer (BC). As data lack on peripheral neuropathy (PN) when using ERI as primary or secondary therapy for recurrent BC, we assessed the incidence of PN, the times to PN onset and recovery, and the risk factors for PN in patients with HER-2-negative recurrent or metastatic BC treated with ERI.


We analyzed data from an ongoing 2-year multicenter prospective observational study where the same number of patients who started ERI administration as primary or secondary therapy and as tertiary or later therapy were enrolled. PN events were defined as new onset or existing PN worsened after ERI administration. Logistic regression was run to assess the risk factors.


The analysis set comprised 458 patients who had completed 6-month follow-up after ERI administration. Mean age ± standard deviation was 59.4 ± 10.9 years, and 171 patients (37.3%) had a history of PN from previous chemotherapy and 190 (41.5%) had existing PN at start of ERI administration (baseline). PN events were observed in 115 patients (25.1%), with severity of Grade 1 in 55 (12.0%), Grade 2 in 51 (11.1%), and Grade 3 in 9 (2.0%) in accordance with the Common Terminology Criteria for Adverse Events version 4.0. After the PN events, 91 patients (79.1%) continued ERI, and 16 (13.9%) reduced the dose or underwent a drug holiday. Within 6 months after ERI administration, 39.0% recovered to the state at baseline. In 266 patients without PN at baseline, new PN appeared in 71 patients (26.7%), and median time to PN onset was 57.0 days (95% confidence interval, 43.0–66.0 days). Results also showed that “history of radiotherapy”, “hemoglobin level”, and “history of PN from previous chemotherapy” were significantly associated with PN events, but no evident association was found with the number of chemotherapy prior to baseline.


PN events were observed in about one-quarter of patients treated with ERI, most of which were mild, and about one-third of patients who developed PN recovered early. This suggests that ERI is well tolerated.

Clinical trial identification

NCT02371174 (First release on November 21, 2014)

Legal entity responsible for the study



Eisai Co., Ltd., Tokyo, Japan


Y. Sakata, H. Iwata, H. Ikezawa, R. Fudetani, D. Tonoda, Y. Uchida, H. Hasegawa, T. Matsuoka: Employee of Eisai Co., Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.